retatrutide side effects clinical trial results 2024 2025 UK Guide: Key Facts on the New Weight-Loss Drug Lilly orforglipron oral GLP-1 phase

It was first studied in Honduras as a treatment for psoriasis [134]

GLP-1 and GIP medical weight loss dosing and progress varies greatly from person to person

In 2024, it also gained FDA approval for a second use: reducing the risk of serious heart problems, such as heart attack and stroke, in adults with cardiovascular disease and obesity or overweight, and in 2025 gained approval for helping treat MASH

A report by medical marketing company Real Chemistry has revealed who is taking these drugs in the U.S., in terms of geography and demographics

These elements also have properties that may overlap in their implementation with each other and IA-1, which together further the goals of the improvement activities ASM performance category